BSE · 524636
Oxygenta Pharmaceutical Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹111 Cr with net profit ₹-10 Cr — a -8.75% net margin, versus -8.77% the period before.
Shareholding
As of 2026-06-30
- Promoter56.54%
- Public43.44%
- DII0.03%
10,196 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.53× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #13 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,05,964 Cr | 274.06 | 12.27 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹27,090 Cr | 205.65 | 16.38 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹24,778 Cr | 116.51 | 13.29 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,677 Cr | 130.36 | 2.19 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,743 Cr | 67.78 | 2.42 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,715 Cr | 110.81 | 4.73 | 12.98% | 11.5% |
| Hikal Limited | ₹2,725 Cr | 188.92 | 2.28 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,247 Cr | 248.28 | 9.18 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹1,998 Cr | 148.14 | 6.07 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,330 Cr | 67.87 | 3.19 | 17.67% | 13.66% |
| Oxygenta Pharmaceutical Limited(this company) | ₹187 Cr | — | — | 41.16% | -10.06% |
AI analysis
AI-generated · google/gemini-2.5-flashOxygenta Pharmaceutical Limited has a market capitalization of Rs 185 Cr. The company reported revenue of Rs 110.61 Cr and a profit margin of -15.56%. The book value per share stands at -11.54, with a return on equity of 41.16% and return on capital employed of -26.02%.
Positives
- +The company's debt-to-equity ratio is 0, indicating no reported debt.
- +Promoter holding of 56.54% as of June 2026 is over 50%.
Negatives
- −The company has a negative profit margin of -15.56%.
- −Net profit has been negative for the past four annual periods, reaching -9.68 Cr in Mar 2025.
- −The book value per share is negative at -11.54.
- −Return on capital employed (ROCE) is significantly negative at -26.02%.
- −Oxygenta Pharmaceutical Limited has reported negative earnings per share for four consecutive annual periods, with EPS of -2.69 in Mar 2025.
Financial performance
The company's revenue increased to Rs 110.61 Cr in Mar 2025 from Rs 39.68 Cr in Mar 2024. Over the last five annual periods, revenue has fluctuated, from Rs 52.12 Cr in Mar 2021 to Rs 110.61 Cr in Mar 2025. Net profit has been negative for the past four years, with a loss of Rs -9.68 Cr in Mar 2025.
Profitability & returns
Oxygenta Pharmaceutical Limited has reported negative profitability, with a profit margin of -15.56%. The return on equity (ROE) for the latest period is 41.16%, while the return on capital employed (ROCE) is -26.02%. The company's earnings per share (EPS) was -2.69 in Mar 2025, continuing a trend of negative EPS since Mar 2022.
Balance sheet
The company has a negative book value per share of -11.54. The debt-to-equity ratio is 0, indicating no debt reported in the provided data. This implies that the company is either debt-free or specific debt figures are not available in the given dataset.
Ownership & pledges
Promoter holding stands at 56.54% as of June 2026. There are no FII holdings reported. The number of shareholders is 10,196. No promoter shares are reported as pledged.
Data as of — price: 2026-07-29 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Oxygenta Pharmaceutical Limitedshare price & fundamentals